Aimei Health Technology Co., Ltd. (AFJK)

The company is a blank check company incorporated as a Cayman Islands exempted company on April 27, 2023, formed to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses, which it calls a target business. It has no operations or revenue-generating business of its own and has not identified or held substantive discussions with any specific target. Its initial public offering was declared effective on November 30, 2023 and closed on December 6, 2023, with 6,900,000 units sold at $10.00 per unit for gross proceeds of $69,000,000, including the fully exercised over-allotment option.

Each unit consists of one ordinary share and one right to receive one-fifth of one ordinary share upon completion of a business combination. Simultaneously, it sold 332,000 private units to Aimei Investment Ltd for $3,320,000. A total of $69,690,000 was placed in a U.S.-based trust account for public shareholders, held in cash or in U.S. government securities or money market funds, until a business combination is completed or the funds are distributed.

If no business combination is completed within the allotted time, the company will redeem public shares from the trust account and wind up. Although its search is not limited by industry or geography, management intends to pursue small-cap companies in North America, Europe and the Asia Pacific region focused on healthcare innovation, including biopharmaceuticals, medical technology and devices, and diagnostics. The company is not targeting China-based companies, though it may consider a target with principal operations in China, Hong Kong or Macau, and it will not pursue targets that operate through variable interest entities.

It cites the experience of its management team, led by its Chief Executive Officer Juan Fernandez Pascual and its Chief Financial Officer Hueng Ming Wong, along with its independent director nominees, as a competitive advantage. Its sponsor has also engaged ARC Group Limited for financial advisory services related to the IPO. The company discusses PRC regulatory, cash-transfer, dividend and currency-conversion considerations that would apply if it combined with a China-based target.

It also cites a HIMSS report indicating that healthcare providers plan to increase investment in technology and digital solutions.